explore -WSS

explore

author：leisure time 2025-09-05 13:44:03 - browse：827

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Cancer, immunology, HIV research ensnared in fetal tissue politics

WSS

STAT letters to the editor on burnt

FDA approves world's first CRISPR

Biotech investment managers search for lucrative opportunities

Roche to buy Carmot Therapeutics, developer of obesity drugs

The woman behind the Dana Farber

Asbestos ban is immediate, but health effects will linger for decades

entertainment

explore

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Asbestos ban is immediate, but health effects will linger for decades

In age of alternative facts, a scholarly course on calling out crap

Erich Jarvis studies song birds to learn about human stuttering

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Leukemia patients are helped by Syndax's new type of therapy

What does generative AI mean for health care? We asked experts

Patients' immediate access to test results puts radiologists in a bind

Wildfire smoke exposes gaps in outdoor worker protections

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

hotspot

CMS should re

Pregnancy discrimination could be enabled by AI

This gene therapy has record $4.25 million price. It's saved children.

Yancopoulos of Regeneron works to expand Dupixent success

This gene therapy has record $4.25 million price. It's saved children.

Cancer, immunology, HIV research ensnared in fetal tissue politics

hotspot

hotspot

hotspot

knowledge